Blockchain Registration Transaction Record

Evolocumab Cuts First Heart Events by 25% in High-Risk Patients

VESALIUS-CV trial shows evolocumab reduces first major cardiovascular events by 25% in high-risk patients without prior heart attack or stroke. Breakthrough PCSK9 inhibitor findings.

This research fundamentally changes preventive cardiovascular care by demonstrating that PCSK9 inhibitors can prevent first major cardiac events in high-risk patients, not just treat existing conditions. For millions of people living with atherosclerotic cardiovascular disease or diabetes who haven't yet experienced a heart attack or stroke, these findings offer a powerful new tool to proactively reduce their cardiovascular risk. The 25% reduction in major events represents a substantial clinical benefit that could prevent thousands of heart attacks, strokes, and deaths annually. Given that cardiovascular disease remains the leading cause of death globally, this advancement in preventive therapy has the potential to significantly impact public health by addressing the gap in primary prevention for high-risk individuals who don't qualify for current secondary prevention strategies.